VivoSim Labs, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VivoSim Labs, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $1.11M | May 31, 2018 |
| FY2018 | Dec 31, 2017 | $1.15M | May 31, 2018 |
| FY2018 | Sep 30, 2017 | $1.36M | May 31, 2018 |
| FY2018 | Jun 30, 2017 | $990.0K | May 31, 2018 |
| FY2018 | Mar 31, 2017 | $812.0K | May 31, 2018 |
| FY2018 | Dec 31, 2016 | $1.15M | May 31, 2018 |
| FY2018 | Sep 30, 2016 | $1.38M | May 31, 2018 |
| FY2018 | Jun 30, 2016 | $891.0K | May 31, 2018 |
| FY2017 | Mar 31, 2016 | $548.0K | Jun 7, 2017 |
| FY2017 | Dec 31, 2015 | $328.0K | Jun 7, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $144.0K | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $109.0K | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $370.0K | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $1.50M | Jul 14, 2023 |
| FY2023 | Feb 22, 2022 | $1.50M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $0 | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | $2.20M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $3.09M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $4.60M | Jun 3, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $3.63M | May 31, 2018 |
| FY2018 | Mar 31, 2017 | $3.17M | May 31, 2018 |
| FY2018 | Mar 31, 2016 | $806.0K | May 31, 2018 |
| FY2017 | Mar 31, 2015 | $314.0K | Jun 7, 2017 |
| FY2016 | Mar 31, 2014 | $0 | Jun 9, 2016 |
| FY2015 | Mar 31, 2013 | $0 | Jun 9, 2015 |
| FY2015 | Dec 31, 2012 | $0 | Jun 9, 2015 |
| FY2015 | Mar 31, 2012 | $0 | Jun 9, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.49M) | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | ($14.67M) | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | ($17.26M) | May 31, 2024 |
| FY2023 | Mar 31, 2022 | ($11.45M) | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | ($16.83M) | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | ($18.71M) | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | ($26.64M) | May 28, 2020 |
| FY2018 | Mar 31, 2018 | ($7.45M) | May 31, 2018 |
| FY2018 | Dec 31, 2017 | ($7.79M) | May 31, 2018 |
| FY2018 | Sep 30, 2017 | ($9.46M) | May 31, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($12.62M) | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | ($15.09M) | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | ($17.73M) | May 31, 2024 |
| FY2023 | Mar 31, 2022 | ($11.48M) | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | ($16.83M) | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | ($21.48M) | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | ($27.27M) | May 28, 2020 |
| FY2019 | Mar 31, 2018 | ($35.27M) | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | ($38.58M) | May 31, 2018 |
| FY2018 | Mar 31, 2016 | ($38.64M) | May 31, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.03M | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $5.50M | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $8.89M | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $3.32M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $1.10M | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | $5.28M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $14.75M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $17.96M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $19.55M | May 31, 2018 |
| FY2018 | Mar 31, 2016 | $18.01M | May 31, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $7.73M | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $9.70M | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $9.22M | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $9.66M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $15.72M | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | $18.06M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $15.13M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $20.89M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $22.30M | May 31, 2018 |
| FY2018 | Mar 31, 2016 | $22.12M | May 31, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($9.46M) | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | ($14.65M) | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | ($12.41M) | May 31, 2024 |
| FY2023 | Mar 31, 2022 | ($8.45M) | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | ($13.32M) | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | ($14.88M) | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | ($20.38M) | May 28, 2020 |
| FY2019 | Mar 31, 2018 | ($28.86M) | Jun 3, 2019 |
| FY2014 | Mar 31, 2014 | ($15.56M) | Jun 10, 2014 |
| FY2012 | Dec 31, 2012 | ($9.69M) | Mar 15, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $13.0K | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $42.0K | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $396.0K | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $409.0K | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $405.0K | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | $0 | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $79.0K | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $226.0K | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $1.35M | May 31, 2018 |
| FY2018 | Mar 31, 2016 | $2.11M | May 31, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $14.65M | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $6.35M | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $20.31M | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $33.30M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $39.92M | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | $28.44M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $40.62M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $49.83M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $69.18M | May 31, 2018 |
| FY2017 | Mar 31, 2016 | $67.58M | Jun 7, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $4.16M | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $2.75M | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $4.98M | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $3.09M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $721.0K | Jun 10, 2022 |
| FY2020 | Mar 31, 2020 | $1.81M | May 28, 2020 |
| FY2020 | Mar 31, 2019 | $4.33M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $5.24M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $6.82M | May 31, 2018 |
| FY2017 | Mar 31, 2016 | $5.40M | Jun 7, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.49M | Jun 5, 2025 |
| FY2025 | Dec 31, 2024 | $364.0K | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $3.60M | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $15.33M | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $30.21M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $39.20M | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | $26.63M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $36.30M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $44.59M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $62.36M | May 31, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($342.16M) | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | ($339.67M) | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | ($325.00M) | May 31, 2024 |
| FY2023 | Mar 31, 2022 | ($307.74M) | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | ($296.29M) | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | ($279.47M) | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | ($260.76M) | May 28, 2020 |
| FY2019 | Mar 31, 2018 | ($234.12M) | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | ($199.32M) | May 31, 2018 |
| FY2017 | Mar 31, 2016 | ($160.87M) | Jun 7, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $11.31M | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | $2.90M | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | $15.30M | May 31, 2024 |
| FY2023 | Mar 31, 2022 | $28.68M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | $37.36M | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | $27.36M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | $36.48M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $43.73M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | $62.75M | May 31, 2018 |
| FY2018 | Mar 31, 2016 | $62.09M | May 31, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (1) | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | (19) | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | (1) | May 31, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Jul 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (1) | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | (19) | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | (1) | May 31, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Jul 14, 2023 |
| FY2012 | Dec 31, 2012 | 0 | Mar 15, 2013 |
| FY2012 | Dec 31, 2011 | 0 | Mar 15, 2013 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 1.90M | Jun 5, 2025 |
| FY2025 | Mar 31, 2024 | 839,814 | Jun 5, 2025 |
| FY2024 | Mar 31, 2023 | 8.72M | May 31, 2024 |
| FY2023 | Mar 31, 2022 | 8.71M | Jul 14, 2023 |
| FY2022 | Mar 31, 2021 | 8.67M | Jun 10, 2022 |
| FY2021 | Mar 31, 2020 | 6.53M | Jun 15, 2021 |
| FY2020 | Mar 31, 2019 | 124.02M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | 111.03M | Jun 3, 2019 |
| FY2018 | Mar 31, 2017 | 104.55M | May 31, 2018 |
| FY2017 | Mar 31, 2016 | 92.39M | Jun 7, 2017 |